WO2007076319A3 - Corps mimetiques humains glp-1 et compositions pour traiter l’obesite et les troubles associes, procedes et utilisations - Google Patents

Corps mimetiques humains glp-1 et compositions pour traiter l’obesite et les troubles associes, procedes et utilisations Download PDF

Info

Publication number
WO2007076319A3
WO2007076319A3 PCT/US2006/062223 US2006062223W WO2007076319A3 WO 2007076319 A3 WO2007076319 A3 WO 2007076319A3 US 2006062223 W US2006062223 W US 2006062223W WO 2007076319 A3 WO2007076319 A3 WO 2007076319A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
related disorders
treating obesity
compositions
mimetibodies
Prior art date
Application number
PCT/US2006/062223
Other languages
English (en)
Other versions
WO2007076319A2 (fr
Inventor
Karyn T O'neil
Kristen Picha
Vedrana Stojanovic-Susulic
Original Assignee
Centocor Inc
Karyn T O'neil
Kristen Picha
Vedrana Stojanovic-Susulic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Inc, Karyn T O'neil, Kristen Picha, Vedrana Stojanovic-Susulic filed Critical Centocor Inc
Priority to EP06846650A priority Critical patent/EP1968645A4/fr
Priority to CA002634784A priority patent/CA2634784A1/fr
Priority to JP2008547703A priority patent/JP2009526750A/ja
Publication of WO2007076319A2 publication Critical patent/WO2007076319A2/fr
Publication of WO2007076319A3 publication Critical patent/WO2007076319A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne au moins un corps mimétique humain atypique GLP-1 ou une portion spécifiée ou sa variante, y compris des acides nucléiques isolés qui codifient au moins un corps mimétique GLP-1 ou une portion spécifiée ou une variante, un corps mimétique GLP-1 ou portion spécifiée ou ses variantes, des vecteurs, des cellules hôtes, des animaux ou plantes transgéniques, et leurs procédés de fabrication et d’utilisation, y compris des compositions, des procédés et des dispositifs thérapeutiques pour traiter les troubles liés à l’obésité.
PCT/US2006/062223 2005-12-22 2006-12-18 Corps mimetiques humains glp-1 et compositions pour traiter l’obesite et les troubles associes, procedes et utilisations WO2007076319A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP06846650A EP1968645A4 (fr) 2005-12-22 2006-12-18 Corps mimetiques humains glp-1 et compositions pour traiter l'obesite et les troubles associes, procedes et utilisations
CA002634784A CA2634784A1 (fr) 2005-12-22 2006-12-18 Corps mimetiques humains glp-1 et compositions pour traiter l'obesite et les troubles associes, procedes et utilisations
JP2008547703A JP2009526750A (ja) 2005-12-22 2006-12-18 Ｇｌｐ−１アゴニスト、組成物、方法および使用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75282605P 2005-12-22 2005-12-22
US60/752,826 2005-12-22

Publications (2)

Publication Number Publication Date
WO2007076319A2 WO2007076319A2 (fr) 2007-07-05
WO2007076319A3 true WO2007076319A3 (fr) 2008-10-30

Family

ID=38218787

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/062223 WO2007076319A2 (fr) 2005-12-22 2006-12-18 Corps mimetiques humains glp-1 et compositions pour traiter l’obesite et les troubles associes, procedes et utilisations

Country Status (4)

Country Link
EP (1) EP1968645A4 (fr)
JP (1) JP2009526750A (fr)
CA (1) CA2634784A1 (fr)
WO (1) WO2007076319A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR064623A1 (es) * 2006-12-21 2009-04-15 Centocor Inc Uso de agonistas del receptor de glp -1 de accion prolongada para mejorar la sensibilidad a la insulina y los perfiles lipidicos
JP2011503000A (ja) * 2007-11-02 2011-01-27 セントコア・オーソ・バイオテツク・インコーポレーテツド 半合成ＧＬＰ−１ペプチド−Ｆｃ融合コンストラクト、その方法及び使用
CN101977932B (zh) 2008-01-31 2014-09-03 美国政府健康及人类服务部 工程化抗体恒定结构域分子
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
MA55504A (fr) 2019-04-01 2022-02-09 Novo Nordisk As Anticorps dirigés contre le liraglutide et leur utilisation
AU2021285138A1 (en) 2020-06-03 2023-02-02 Københavns Universitet GLP1R agonist NMDAR antagonist conjugates

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005097175A2 (fr) * 2004-03-31 2005-10-20 Centocor, Inc. Corps mimetiques glp-1 humains, compositions, procedes et utilisations

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005097175A2 (fr) * 2004-03-31 2005-10-20 Centocor, Inc. Corps mimetiques glp-1 humains, compositions, procedes et utilisations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1968645A4 *

Also Published As

Publication number Publication date
JP2009526750A (ja) 2009-07-23
WO2007076319A2 (fr) 2007-07-05
EP1968645A4 (fr) 2009-11-04
CA2634784A1 (fr) 2007-07-05
EP1968645A2 (fr) 2008-09-17

Similar Documents

Publication Publication Date Title
WO2005097175A3 (fr) Corps mimetiques glp-1 humains, compositions, procedes et utilisations
WO2008011446A3 (fr) Mimétiques de la glp-1 humaine, compositions, procédés et utilisations
WO2005081687A3 (fr) Mimeticorps de noyau-charniere humain, compositions, procedes et applications correspondantes
WO2007046834A3 (fr) Agonistes glp-1, compositions, procedes et utilisations
WO2005032460A3 (fr) Mimeticorps de noyau charniere mimetiques de l'epo humaine, compositions, procedes et applications correspondantes
WO2004002417A3 (fr) Corps mimetiques mammaliens a deletion ch1, compositions, procedes et utilisations
WO2003084477A3 (fr) Corps mimetiques de cdr de mammifere, compositions, procedes et utilisations
WO2006124451A3 (fr) Anticorps anti-il-13, compositions, procedes et utilisations
UA101301C2 (ru) ВЫДЕЛЕННОЕ АНТИТЕЛО ПРОТИВ IL-23pl 9 И ЕГО ПРИМЕНЕНИЕ
MX2010004179A (es) Anticuerpos anti-amiloide, composiciones, metodos y usos.
WO2005028511A3 (fr) Anticorps anti-amyloides, compositions, procedes et utilisations
IL195898A (en) Isolated antibody tnf binding, its compounds and its uses in the preparation of drugs for the treatment of diseases
WO2009133573A3 (fr) Formulation homéopathique
WO2005116088A3 (fr) Methodes et compositions pour traiter des maladies et des troubles associes a des cellules exprimant siglec-8
WO2007022506A3 (fr) Méthodes et préparations pour le traitement d'une maladie neurologique
WO2002072788A3 (fr) Proteines provenant de l'immunoglobuline associees a la bronchopneumopathie chronique obstructive, compositions, procedes et utilisations
WO2005005604A3 (fr) Proteines derivees de l'immunoglobuline anti-cible et genetiquement modifiees, compositions, procedes et utilisations
WO2003086451A8 (fr) Proteines derivees de l'immunoglobuline anti il-13 associees a l'asthme, compositions, procedes et utilisations associes
WO2005091853A3 (fr) Procedes et compositions pour traiter des pathologies associees a l'il-13
WO2009052431A3 (fr) Agents de liaison au cd19 et utilisations de ceux-ci
WO2006036745A3 (fr) Proteines derivees de l'immunoglobuline specifiques de il-23p40, compositions, epitopes, procedes et utilisations
WO2006105538A3 (fr) Methodes et compositions de traitement de pathologies afferentes a l'il-21
WO2007076319A3 (fr) Corps mimetiques humains glp-1 et compositions pour traiter l’obesite et les troubles associes, procedes et utilisations
WO2003074073A3 (fr) Genes impliques dans la regulation de l'angiogenese, preparations pharmaceutiques les contenant et leurs applications.
WO2006135694A3 (fr) Composes modulateurs d'uii et utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2008547703

Country of ref document: JP

Ref document number: 2634784

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006846650

Country of ref document: EP